Dual‐hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions

Author:

Infante Marco123ORCID,Baidal David A.14,Rickels Michael R.5,Fabbri Andrea2,Skyler Jay S.4,Alejandro Rodolfo14,Ricordi Camillo1

Affiliation:

1. Clinical Cell Transplant Program Diabetes Research Institute University of Miami Miller School of Medicine Miami FL USA

2. Division of Endocrinology, Metabolism and Diabetes Department of Systems Medicine CTO A. Alesini Hospital Diabetes Research Institute Federation University of Rome Tor Vergata Rome Italy

3. UniCamillus Saint Camillus International University of Health Sciences Rome Italy

4. Division of Endocrinology, Diabetes and Metabolism Department of Medicine Diabetes Research Institute University of Miami Miller School of Medicine Miami FL USA

5. Division of Endocrinology, Diabetes and Metabolism Department of Medicine Institute for Diabetes, Obesity and Metabolism University of Pennsylvania Perelman School of Medicine Philadelphia PA USA

Publisher

Wiley

Subject

Biomedical Engineering,General Medicine,Biomaterials,Medicine (miscellaneous),Bioengineering

Reference159 articles.

1. Type 1 diabetes

2. Editorial—Moving forward on the pathway of targeted immunotherapies for type 1 diabetes: the importance of disease heterogeneity;Infante M;Eur Rev Med Pharmacol Sci,2019

3. Hope vs hype: where are we in type 1 diabetes?

4. Advances in β-cell replacement therapy for the treatment of type 1 diabetes

5. Technology in the management of type 1 diabetes mellitus — current status and future prospects

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3